Deramiocel (CAP-1002)

Name: Deramiocel (CAP-1002) in Duchenne muscular dystrophy: Mechanism of action
Published: 2026-09-14T15:39:06-04:00

Duchenne muscular dystrophy

Manufacturer: Capricor Therapeutics
Regulatory submission: Class 2 BLA resubmission submitted February 2026
Launch: Not announced
Last updated: September 19, 2026

Section

Product information and disease description Product description Product information Pharmacology

Mechanism of action

1 evidence topic · 1 source

Proposed mechanism of action

“CDCs are not stem cells and do not engraft. They exert their anti-fibrotic and anti-inflammatory effects through the release of exosomes.” (opens the source at this quote in a new tab)